FNY Investment Advisers’s Sonnet BioTherapeutics SONN Stock Holding History

FNY Investment Advisers’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1	Closed	–	–	733
2022 Q3	$0	Buy	+1	New	+$584	﹤0.01%	824

Other funds holding SONN

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FNY Investment Advisers's SONN Position: Q4 2022 in Review

FNY Investment Advisers sold out of Sonnet BioTherapeutics (SONN) in Q4 2022, closing a stake of 1 share.

FNY Investment Advisers first reported a position in SONN in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 11 funds tracked by Wall St. Rank hold SONN as of Q4 2022.

FNY Investment Advisers reported no remaining Sonnet BioTherapeutics position as of Q4 2022 after selling out during the quarter.
FNY Investment Advisers sold 1 Sonnet BioTherapeutics share in Q4 2022.
FNY Investment Advisers first reported a position in Sonnet BioTherapeutics in Q3 2022 and held it in 1 quarter.
FNY Investment Advisers's Sonnet BioTherapeutics position peaked at $0 in Q3 2022.
11 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2022.

Based on FNY Investment Advisers's 13F filing for Q4 2022, filed 10 Jan 2023.